Key facts
- This page summarizes Thomas Andrew Davis's Form 4 filing for GENOCEA BIOSCIENCES, INC..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Mar 2022, 16:09.
Thomas Andrew Davis - 15 Mar 2022 Form 4 Insider Report for GENOCEA BIOSCIENCES, INC.
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- N/A
- Reported as of
- 15 Mar 2022
- Net transaction value
- -$2,989
- SEC form
- 4
- Accepted by SEC
- 17 Mar 2022, 16:09:09 UTC
- Prior SEC filing
- 16 Mar 2022
- Next SEC filing
- 05 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Diantha Duvall, Attorney-in-Fact for Thomas Davis
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas Andrew Davis filed Form 4 for GENOCEA BIOSCIENCES, INC. on 17 Mar 2022.
Change
- Previous filing in this sequence was filed on 16 Mar 2022.
- Current net transaction value: -$2,989.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GNCA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +31,250
- Change %
- +76%
- Price
- $0.000000
- Shares after
- 72,138
- Date
- 15 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
GNCA
transaction
Common Stock
Sale
- Transaction value
- $2,989
- Shares
- -2,717
- Change %
- -3.8%
- Price
- $1.10
- Shares after
- 69,421
- Date
- 16 Mar 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GNCA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +93,750
- Change %
- Price
- $0.000000
- Shares after
- 93,750
- Date
- 15 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 93,750
- Exercise price
- $1.11
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date.
Footnote F2
Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person.
Footnote F3
The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date.